Business
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S. Food and Drug Administration’s (“FDA”) Orange Book HALIFAX, Nova Scotia, April 28, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, tod
About this update from Appili Therapeutics Inc Class A
[{"type":"image","alt":"Appili Therapeutics Inc.","displaySize":"","headline":null,"caption":"Appili Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":174,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/0ffbb964adae4c4c44e58e70f361d392"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Gm4iD2zljen4lWwIosNX4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTc0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0ffbb964adae4c4c44e58e70f361d392","width":174,"height":61}},"lazy":false},{"type":"text","content":"New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ","length":159,"tagName":"p"},{"type":"text","content":"New subject matter listed in the U.S. Food and Drug Administration’s (“FDA”) Orange Book","length":88,"tagName":"p"},{"type":"text","content":"HALIFAX, Nova Scotia, April 28, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the United States Patent and Trademark Office and the Mexican Patent Office have granted new patent claims protecting its oral formulation of metronidazole, LIKMEZ®™.","length":445,"tagName":"p"},{"type":"text","content":"The newly granted patents include:","length":34,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"U.S. patent no. 20230086660A1 - Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"Mexican patent no. 2020007494 - Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same","length":114,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":228,"olType":false},{"type":"text","content":"The two new patents, set to expire in 2039 provide comprehensive protection for LIKMEZ, covering its unique taste masked composition and accessible therapeutic applications. Our partner, Saptalis Pharmaceuticals, LLC, has successfully undertaken the necessary steps to have the U.S. patent listed in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).","length":386,"tagName":"p"},{"type":"text","con...